Newsletter | July 17, 2025

07.17.25 -- Techniques To Streamline Development From Feasibility To Launch

Analytical-Driven Cell Therapy Development

Explore the escalating rigor from assessing feasibility in preclinical studies to fully validated release methods and lifecycle management in commercial supply.

 

Impact Of Media Selection

To highlight the importance of media selection, a study was conducted assessing the effect of three commercially available cGMP grade medias and their influence on T-cell phenotype.

 

DOE Methodology Reduces Cost, Time For Method Development

Here, we illustrate how our Design of Experiment (DoE) can accelerate development timelines, lower costs, and enhance decision-making across cell therapy programs.

 

SOLUTIONS

Your CDMO Partner From Development To Supply

Discover a platform that offers clients a personalized, responsive, and expert-driven approach to process development and manufacturing from early clinical to pivotal supply and commercial launch.

• Request Information

 

 

 

Capacity Update April 2025: Cell & Gene Therapy

Examine how expert CMC strategies and clinical manufacturing experience can lay the groundwork for the successful commercialization of advanced cell therapies, helping to ensure quality and scalability.

• Request Information